Australia - English - Department of Health (Therapeutic Goods Administration)

janssen-cilag pty ltd - ibrutinib, quantity: 280 mg - tablet, film coated - excipient ingredients: lactose monohydrate; croscarmellose sodium; sodium lauryl sulfate; povidone; microcrystalline cellulose; colloidal anhydrous silica; magnesium stearate; titanium dioxide; purified talc; iron oxide red; polyvinyl alcohol; macrogol 3350; iron oxide black - imbruvica is indicated for the treatment of patients with mcl who have received at least one prior therapy.,imbruvica as a single agent is indicated for the treatment of adult patients with waldenstr?m?s macroglobulinaemia (wm) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo-immunotherapy.,imbruvica in combination with rituximab is indicated for the treatment of adult patients with waldenstrom?s macroglobulinaemia (wm).,imbruvica as a single agent or in combination with rituximab or obinutuzumab or venetoclax is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia/small lymphocytic lymphoma (cll/sll).,imbruvica as a single agent or in combination with bendamustine and rituximab (br) is indicated for the treatment of adult patients with chronic lymphocytic leukaemia/small lymphocytic lymphoma (cll/sll) who have received at least one prior therapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

janssen-cilag pty ltd - ibrutinib, quantity: 140 mg - tablet, film coated - excipient ingredients: lactose monohydrate; croscarmellose sodium; sodium lauryl sulfate; povidone; microcrystalline cellulose; colloidal anhydrous silica; magnesium stearate; titanium dioxide; purified talc; iron oxide yellow; polyvinyl alcohol; macrogol 3350; iron oxide black - imbruvica is indicated for the treatment of patients with mcl who have received at least one prior therapy.,imbruvica as a single agent is indicated for the treatment of adult patients with waldenstr?m?s macroglobulinaemia (wm) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo-immunotherapy.,imbruvica in combination with rituximab is indicated for the treatment of adult patients with waldenstrom?s macroglobulinaemia (wm).,imbruvica as a single agent or in combination with rituximab or obinutuzumab or venetoclax is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia/small lymphocytic lymphoma (cll/sll).,imbruvica as a single agent or in combination with bendamustine and rituximab (br) is indicated for the treatment of adult patients with chronic lymphocytic leukaemia/small lymphocytic lymphoma (cll/sll) who have received at least one prior therapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

janssen-cilag pty ltd - risperidone, quantity: 50 mg - injection, modified release - excipient ingredients: polysorbate 20; water for injections; sodium hydroxide; dibasic sodium phosphate dihydrate; sodium chloride; citric acid; carmellose sodium - risperdal consta is indicated for the treatment of schizophrenia and related psychoses. risperdal consta is indicated for monotherapy for maintenance treatment to prevent the recurrence of manic or mixed episodes of bipolar i disorder in patients with a manic or mixed episode, following stabilisation with oral risperidone. adjunctive maintenance treatment with lithium or sodium valproate in treatment refractory patients with bipolar i disorder who have at least 4 relapses in a 12 month period.

Australia - English - Department of Health (Therapeutic Goods Administration)

janssen-cilag pty ltd - risperidone, quantity: 37.5 mg - injection, modified release - excipient ingredients: citric acid; sodium chloride; carmellose sodium; polysorbate 20; dibasic sodium phosphate dihydrate; sodium hydroxide; water for injections - risperdal consta is indicated for the treatment of schizophrenia and related psychoses. risperdal consta is indicated for monotherapy for maintenance treatment to prevent the recurrence of manic or mixed episodes of bipolar i disorder in patients with a manic or mixed episode, following stabilisation with oral risperidone. adjunctive maintenance treatment with lithium or sodium valproate in treatment refractory patients with bipolar i disorder who have at least 4 relapses in a 12 month period.

Australia - English - Department of Health (Therapeutic Goods Administration)

janssen-cilag pty ltd - risperidone, quantity: 25 mg - injection, modified release - excipient ingredients: sodium hydroxide; citric acid; sodium chloride; carmellose sodium; dibasic sodium phosphate dihydrate; polysorbate 20; water for injections - risperdal consta is indicated for the treatment of schizophrenia and related psychoses. risperdal consta is indicated for monotherapy for maintenance treatment to prevent the recurrence of manic or mixed episodes of bipolar i disorder in patients with a manic or mixed episode, following stabilisation with oral risperidone. adjunctive maintenance treatment with lithium or sodium valproate in treatment refractory patients with bipolar i disorder who have at least 4 relapses in a 12 month period.

Australia - English - Department of Health (Therapeutic Goods Administration)

janssen-cilag pty ltd - risperidone, quantity: 0.5 mg - tablet, film coated - excipient ingredients: titanium dioxide; hypromellose; propylene glycol; maize starch; sodium lauryl sulfate; magnesium stearate; purified talc; iron oxide red; colloidal anhydrous silica; lactose monohydrate; microcrystalline cellulose - risperdal is indicated for the treatment of schizophrenia and related psychoses. risperdal is indicated for the short term treatment of acute mania associated with bipolar 1 disorder. risperdal is also indicated for the treatment of behavioural disturbances in dementia. risperdal is indicated in the treatment of conduct and other disruptive behaviour disorders in children (over 5 years), adolescents and adults with sub-average intellectual functioning or mental retardation in whom destructive behaviours (e.g. aggression, impulsivity and self-injurious behaviours) are prominent (see clinical trials for maintenance data). risperdal is indicated for the treatment of behavioural disorders associated with autism in children and adolescents (see clinical trials).

Australia - English - Department of Health (Therapeutic Goods Administration)

janssen-cilag pty ltd - risperidone, quantity: 1 mg/ml - oral liquid, solution - excipient ingredients: purified water; benzoic acid; tartaric acid; sodium hydroxide - risperdal is indicated for the treatment of schizophrenia and related psychoses. risperdal is indicated for the short term treatment of acute mania associated with bipolar 1 disorder. risperdal is also indicated for the treatment of behavioural disturbances in dementia. risperdal is indicated in the treatment of conduct and other disruptive behaviour disorders in children (over 5 years), adolescents and adults with sub-average intellectual functioning or mental retardation in whom destructive behaviours (e.g. aggression, impulsivity and self-injurious behaviours) are prominent (see clinical trials for maintenance data). risperdal is indicated for the treatment of behavioural disorders associated with autism in children and adolescents (see clinical trials).

Australia - English - Department of Health (Therapeutic Goods Administration)

janssen-cilag pty ltd - risperidone, quantity: 2 mg - tablet, film coated - excipient ingredients: lactose monohydrate; maize starch; sunset yellow fcf; hypromellose; microcrystalline cellulose; propylene glycol; titanium dioxide; sodium lauryl sulfate; colloidal anhydrous silica; purified talc; magnesium stearate - risperdal is indicated for the treatment of schizophrenia and related psychoses. risperdal is indicated for the short term treatment of acute mania associated with bipolar 1 disorder. risperdal is also indicated for the treatment of behavioural disturbances in dementia. risperdal is indicated in the treatment of conduct and other disruptive behaviour disorders in children (over 5 years), adolescents and adults with sub-average intellectual functioning or mental retardation in whom destructive behaviours (e.g. aggression, impulsivity and self-injurious behaviours) are prominent (see clinical trials for maintenance data). risperdal is indicated for the treatment of behavioural disorders associated with autism in children and adolescents (see clinical trials).

Australia - English - Department of Health (Therapeutic Goods Administration)

janssen-cilag pty ltd - risperidone, quantity: 4 mg - tablet, film coated - excipient ingredients: indigo carmine; colloidal anhydrous silica; sodium lauryl sulfate; purified talc; quinoline yellow; microcrystalline cellulose; hypromellose; magnesium stearate; propylene glycol; maize starch; lactose monohydrate; titanium dioxide - risperdal is indicated for the treatment of schizophrenia and related psychoses. risperdal is indicated for the short term treatment of acute mania associated with bipolar 1 disorder. risperdal is also indicated for the treatment of behavioural disturbances in dementia. risperdal is indicated in the treatment of conduct and other disruptive behaviour disorders in children (over 5 years), adolescents and adults with sub-average intellectual functioning or mental retardation in whom destructive behaviours (e.g. aggression, impulsivity and self-injurious behaviours) are prominent (see clinical trials for maintenance data). risperdal is indicated for the treatment of behavioural disorders associated with autism in children and adolescents (see clinical trials).

Australia - English - Department of Health (Therapeutic Goods Administration)

janssen-cilag pty ltd - risperidone, quantity: 3 mg - tablet, film coated - excipient ingredients: hypromellose; purified talc; lactose monohydrate; maize starch; sodium lauryl sulfate; microcrystalline cellulose; titanium dioxide; quinoline yellow; colloidal anhydrous silica; magnesium stearate; propylene glycol - risperdal is indicated for the treatment of schizophrenia and related psychoses. risperdal is indicated for the short term treatment of acute mania associated with bipolar 1 disorder. risperdal is also indicated for the treatment of behavioural disturbances in dementia. risperdal is indicated in the treatment of conduct and other disruptive behaviour disorders in children (over 5 years), adolescents and adults with sub-average intellectual functioning or mental retardation in whom destructive behaviours (e.g. aggression, impulsivity and self-injurious behaviours) are prominent (see clinical trials for maintenance data). risperdal is indicated for the treatment of behavioural disorders associated with autism in children and adolescents (see clinical trials).